Back to today’s briefing

Story perspectives

Evaxion Unveils Cancer Vaccine Breakthrough at AACR 2025

3/26/2025

39 9

Summary

Story summary

Evaxion Biotech is set to unveil groundbreaking biomarker and immune data for its personalized cancer vaccine, EVX-01, at the AACR Annual Meeting in Chicago from April 25-30, 2025. This innovative phase 2 trial, focusing on advanced melanoma, is poised for a significant two-year clinical data readout by late 2025, showcasing promising response rates that could change lives.

1 of 1

Story summary

Evaxion Biotech is set to unveil groundbreaking biomarker and immune data for its personalized cancer vaccine, EVX-01, at the AACR Annual Meeting in Chicago from April 25-30, 2025. This innovative phase 2 trial, focusing on advanced melanoma, is poised for a significant two-year clinical data readout by late 2025, showcasing promising response rates that could change lives.